UBS Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Acadia Pharmaceuticals (ACAD) PT Lowered to $21 at Oppenheimer
September 24, 2025 3:41 PM EDTOppenheimer analyst Matthew Hershenhorn lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $21.00 (from $22.00) while maintaining a Perform rating.
The analyst comments "We anticipated a higher likelihood of ACP-101 missing the primary endpoint of the Ph3 COMPASS-PWS study, driving underperformance today... More
Acadia Pharmaceuticals (ACAD) PT Lowered to $35 at TD Cowen
September 24, 2025 3:38 PM EDTTD Cowen analyst Ritu Baral lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $35.00 (from $39.00) while maintaining a Buy rating.
The analyst comments "ACAD announced that ACP-101 (intranasal carbetocin) missed in the Ph3 Prader Willi study, failing to separate from... More
BofA Son Acadia (ACAD): 'our focus continues to be on the reacceleration of the Daybue launch in Rett syndrome'
September 24, 2025 10:23 AM EDTBofA Securities analyst Tazeen Ahmad reiterated a Neutral rating and $27.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).
The analyst comments "ACAD announced the ph 3 COMPASS PWS study evaluating ACP-101 (intranasal carbetocin) in patients with hyperphagia in Prader-Willi syndrome (PWS) failed to... More
Baird: 'Acadia shares should come out relatively unscathed after the dust settles'
September 24, 2025 9:29 AM EDTBaird analyst Joel Beatty reiterated an Outperform rating and $31.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).
The analyst comments "No change to outlook on clinical trial update. This morning, Acadia announced the Phase 3 COMPASS study of ACP-101 in PWS did not meet the... More
BMO Capital: 'expect ACAD shares to decline'
September 24, 2025 8:05 AM EDTBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $28.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).
The analyst comments "ACP-101 miss in PWS represents a meaningful step back in Acadia's R&D development plans. Ph 3 results from the company's COMPASS... More
